Sara Margolin

20.2k total citations
39 papers, 733 citations indexed

About

Sara Margolin is a scholar working on Genetics, Cancer Research and Oncology. According to data from OpenAlex, Sara Margolin has authored 39 papers receiving a total of 733 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Genetics, 17 papers in Cancer Research and 11 papers in Oncology. Recurrent topics in Sara Margolin's work include BRCA gene mutations in cancer (14 papers), Breast Cancer Treatment Studies (11 papers) and Estrogen and related hormone effects (8 papers). Sara Margolin is often cited by papers focused on BRCA gene mutations in cancer (14 papers), Breast Cancer Treatment Studies (11 papers) and Estrogen and related hormone effects (8 papers). Sara Margolin collaborates with scholars based in Sweden, Norway and Germany. Sara Margolin's co-authors include Annika Lindblom, Yvonne Wengström, Barbro Werelius, L Thorén, Helene Rundqvist, Per Hall, Anna Jervaeus, Sara Mijwel, Maria Browall and Kate A. Bolam and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Sara Margolin

34 papers receiving 710 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sara Margolin Sweden 15 316 279 223 172 130 39 733
Mitul Shah United Kingdom 16 337 1.1× 286 1.0× 389 1.7× 191 1.1× 93 0.7× 22 967
Yon‐Dschun Ko Germany 19 277 0.9× 141 0.5× 444 2.0× 140 0.8× 151 1.2× 63 917
Bo Lin China 14 264 0.8× 258 0.9× 215 1.0× 144 0.8× 72 0.6× 36 753
Chiyo K. Imamura Japan 14 326 1.0× 235 0.8× 212 1.0× 98 0.6× 113 0.9× 54 795
Galina Lurie United States 18 341 1.1× 195 0.7× 79 0.4× 122 0.7× 259 2.0× 23 827
Andrea M. Nibbe United States 7 354 1.1× 306 1.1× 200 0.9× 266 1.5× 66 0.5× 9 717
Hoffmann-La Roche France 8 256 0.8× 113 0.4× 87 0.4× 125 0.7× 91 0.7× 15 446
Marike Gabrielson Sweden 14 251 0.8× 123 0.4× 153 0.7× 195 1.1× 169 1.3× 32 573
Mohan C. Pant India 20 212 0.7× 70 0.3× 539 2.4× 144 0.8× 139 1.1× 40 933

Countries citing papers authored by Sara Margolin

Since Specialization
Citations

This map shows the geographic impact of Sara Margolin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Margolin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Margolin more than expected).

Fields of papers citing papers by Sara Margolin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Margolin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Margolin. The network helps show where Sara Margolin may publish in the future.

Co-authorship network of co-authors of Sara Margolin

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Margolin. A scholar is included among the top collaborators of Sara Margolin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Margolin. Sara Margolin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Wen, Xue Min Wang, Hafdís T. Helgadóttir, et al.. (2025). A Swedish genome-wide haplotype association analysis identifies novel candidate loci associated with endometrial cancer risk. PLoS ONE. 20(3). e0316086–e0316086.
2.
3.
Liu, Wen, Patrick Bryant, Jessada Thutkawkorapin, et al.. (2023). A Swedish Familial Genome-Wide Haplotype Analysis Identified Five Novel Breast Cancer Susceptibility Loci on 9p24.3, 11q22.3, 15q11.2, 16q24.1 and Xq21.31. International Journal of Molecular Sciences. 24(5). 4468–4468. 4 indexed citations
4.
Graßmann, Felix, Anders Mälarstig, Matilda Dale, et al.. (2023). The impact of circulating protein levels identified by affinity proteomics on short-term, overall breast cancer risk. British Journal of Cancer. 130(4). 620–627. 4 indexed citations
5.
Thorén, L, Sara Margolin, Erik Eliasson, Jonas Bergh, & Jonatan D. Lindh. (2023). Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records. Breast Cancer Research and Treatment. 198(3). 499–508. 2 indexed citations
6.
Garmo, Hans, et al.. (2023). Estrogen therapy after breast cancer diagnosis and breast cancer mortality risk. Breast Cancer Research and Treatment. 198(2). 361–368. 8 indexed citations
7.
Liu, Wen, Hafdís T. Helgadóttir, Kyriaki Michailidou, et al.. (2022). A Swedish Genome-Wide Haplotype Association Analysis Identifies a Novel Breast Cancer Susceptibility Locus in 8p21.2 and Characterizes Three Loci on Chromosomes 10, 11 and 16. Cancers. 14(5). 1206–1206. 5 indexed citations
8.
Chen, Xinsong, Emmanouil G. Sifakis, Stephanie Robertson, et al.. (2022). 1668P Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction. Annals of Oncology. 33. S1306–S1306. 1 indexed citations
9.
Thorén, L, Mikael Eriksson, Jonatan D. Lindh, et al.. (2021). Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients. Breast Cancer Research and Treatment. 190(3). 451–462. 2 indexed citations
10.
He, Wei, Felix Graßmann, Mikael Eriksson, et al.. (2019). CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer. Journal of Clinical Oncology. 38(6). 548–557. 34 indexed citations
11.
Matikas, Alexios, Sara Margolin, Mats Hellström, et al.. (2017). Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer. Breast Cancer Research and Treatment. 168(2). 349–355. 7 indexed citations
12.
Mijwel, Sara, Malin Backman, Kate A. Bolam, et al.. (2017). Adding high-intensity interval training to conventional training modalities: optimizing health-related outcomes during chemotherapy for breast cancer: the OptiTrain randomized controlled trial. Breast Cancer Research and Treatment. 168(1). 79–93. 126 indexed citations
13.
Lindblom, Annika, et al.. (2015). Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden. Hereditary Cancer in Clinical Practice. 13(1). 15–15. 10 indexed citations
14.
Falato, Claudette, et al.. (2014). A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden. Acta Oncologica. 54(4). 527–534. 16 indexed citations
15.
Jansson, Agneta, Jonas Carlsson, Petter Storm, et al.. (2007). A new polymorphism in the coding region of exon four in HSD17B2 in relation to risk of sporadic and hereditary breast cancer. Breast Cancer Research and Treatment. 106(1). 57–64. 11 indexed citations
16.
Margolin, Sara, Hemming Johansson, Lars Erik Rutqvist, Annika Lindblom, & Tommy� Fornander. (2006). Family History, and Impact on Clinical Presentation and Prognosis, in a Population-based Breast Cancer Cohort from the Stockholm County. Familial Cancer. 5(4). 309–321. 27 indexed citations
17.
Maguire, Paula, Sara Margolin, Sun Xiao, et al.. (2005). Estrogen Receptor Beta (ESR2) Polymorphisms in Familial and Sporadic Breast Cancer. Breast Cancer Research and Treatment. 94(2). 145–152. 53 indexed citations
18.
Margolin, Sara, Barbro Werelius, Tommy� Fornander, & Annika Lindblom. (2004). BRCA1 Mutations in a Population-based Study of Breast Cancer in Stockholm County. Genetic Testing. 8(2). 127–132. 16 indexed citations
19.
Lei, Haixin, Sara Margolin, Sima Salahshor, et al.. (2001). CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk. International Journal of Cancer. 98(2). 199–204. 69 indexed citations
20.
Salahshor, Sima, Haixin Lei, Vessela N. Kristensen, et al.. (2001). Low frequency of E-cadherinalterations in familial breast cancer. Breast Cancer Research. 3(3). 199–207. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mitul Shah Breakdown of academic impact, for papers by Yon‐Dschun Ko Breakdown of academic impact, for papers by Bo Lin Breakdown of academic impact, for papers by Chiyo K. Imamura Breakdown of academic impact, for papers by Galina Lurie Breakdown of academic impact, for papers by Andrea M. Nibbe Breakdown of academic impact, for papers by Hoffmann-La Roche Breakdown of academic impact, for papers by Marike Gabrielson Breakdown of academic impact, for papers by Mohan C. Pant
Rankless by CCL
2026